1. Home
  2. PZZA vs NGNE Comparison

PZZA vs NGNE Comparison

Compare PZZA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Papa John's International Inc.

PZZA

Papa John's International Inc.

N/A

Current Price

$18.40

Market Cap

640.7M

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$27.30

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PZZA
NGNE
Founded
1984
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.7M
744.9M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
PZZA
NGNE
Price
$18.40
$27.30
Analyst Decision
Hold
Strong Buy
Analyst Count
13
10
Target Price
$28.00
★ $77.88
AVG Volume (30 Days)
★ 1.3M
328.7K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
★ 7.34%
N/A
EPS Growth
N/A
★ 0.93
EPS
★ 0.46
N/A
Revenue
★ $2,068,421,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$40.64
★ N/A
Revenue Growth
★ 14.07
N/A
52 Week Low
$17.70
$15.93
52 Week High
$52.02
$43.66

Technical Indicators

Market Signals
Indicator
PZZA
NGNE
Relative Strength Index (RSI) 38.96 50.19
Support Level $17.70 $24.88
Resistance Level $24.25 $28.47
Average True Range (ATR) 0.63 2.43
MACD 0.09 0.87
Stochastic Oscillator 32.75 56.16

Price Performance

Historical Comparison
PZZA
NGNE

About PZZA Papa John's International Inc.

Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: